Pseudomonas aeruginosa exoproducts determine antibiotic efficacy against Staphylococcus aureus by Radlinski, Lauren et al.
RESEARCH ARTICLE
Pseudomonas aeruginosa exoproducts
determine antibiotic efficacy against
Staphylococcus aureus
Lauren Radlinski1, Sarah E. Rowe1, Laurel B. Kartchner1,2, Robert Maile1,2, Bruce
A. Cairns1,2, Nicholas P. Vitko3, Cindy J. Gode3, Anne M. Lachiewicz2,4, Matthew
C. Wolfgang1,3, Brian P. Conlon1,3*
1 Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina,
United States of America, 2 North Carolina Jaycee Burn Center, University of North Carolina at Chapel Hill,
North Carolina, United States of America, 3 Marsico Lung Institute, University of North Carolina at Chapel
Hill, North Carolina, United States of America, 4 Division of Infectious Diseases, University of North Carolina
at Chapel Hill, North Carolina, United States of America
* bconlon@med.unc.edu
Abstract
Chronic coinfections of Staphylococcus aureus and Pseudomonas aeruginosa frequently
fail to respond to antibiotic treatment, leading to significant patient morbidity and mortality.
Currently, the impact of interspecies interaction on S. aureus antibiotic susceptibility
remains poorly understood. In this study, we utilize a panel of P. aeruginosa burn wound
and cystic fibrosis (CF) lung isolates to demonstrate that P. aeruginosa alters S. aureus sus-
ceptibility to bactericidal antibiotics in a variable, strain-dependent manner and further iden-
tify 3 independent interactions responsible for antagonizing or potentiating antibiotic activity
against S. aureus. We find that P. aeruginosa LasA endopeptidase potentiates lysis of S.
aureus by vancomycin, rhamnolipids facilitate proton-motive force-independent tobramycin
uptake, and 2-heptyl-4-hydroxyquinoline N-oxide (HQNO) induces multidrug tolerance in S.
aureus through respiratory inhibition and reduction of cellular ATP. We find that the produc-
tion of each of these factors varies between clinical isolates and corresponds to the capacity
of each isolate to alter S. aureus antibiotic susceptibility. Furthermore, we demonstrate that
vancomycin treatment of a S. aureus mouse burn infection is potentiated by the presence of
a LasA-producing P. aeruginosa population. These findings demonstrate that antibiotic sus-
ceptibility is complex and dependent not only upon the genotype of the pathogen being tar-
geted, but also on interactions with other microorganisms in the infection environment.
Consideration of these interactions will improve the treatment of polymicrobial infections.
Author summary
Accurate prediction of antimicrobial efficacy is essential for successful treatment of a bac-
terial infection. While many studies have considered the impacts of genetically encoded
mechanisms of resistance, nongenetic determinants of antibiotic susceptibility during
infection remain poorly understood. Here we show that a single interspecies interaction
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between 2 human pathogens, S. aureus and P. aeruginosa, can completely transform the
antibiotic susceptibility profile of S. aureus. Through multiple distinct mechanisms, P. aer-
uginosa can antagonize or potentiate the efficacy of multiple classes of antibiotics against
S. aureus. We identify the exoproducts responsible for altering S. aureus susceptibility to
antibiotic killing, and furthermore demonstrate that these compounds are produced at
varying levels in P. aeruginosa clinical isolates, with dramatic repercussions for S. aureus
antibiotic susceptibility. Finally, we use a mouse model of P. aeruginosa–S. aureus coinfec-
tion to demonstrate that the presence of P. aeruginosa significantly alters the outcome of
S. aureus antibiotic therapy in a host. These findings indicate that the efficacy of antibiotic
treatment in polymicrobial infection is determined at the community level, with interspe-
cies interaction playing an important and previously unappreciated role.
Introduction
S. aureus is responsible for numerous chronic and relapsing infections such as osteomyelitis,
endocarditis, and infections of the cystic fibrosis (CF) lung, as well as many penetrating trauma
and burn infections, venous leg ulcers, pressure ulcers, and diabetic foot ulcers. These infec-
tions are notoriously difficult to treat, despite isolates frequently exhibiting full sensitivity to
administered antibiotics, as measured in vitro using a Minimum Inhibitory Concentration
(MIC) assay. This suggests that environmental factors present in vivo may influence the patho-
gen’s susceptibility to antibiotic killing. While these factors can include physical barriers to
antibiotic activity, such as tissue necrosis and low vascularization at a site of infection, or bacte-
rial replication within host phagocytes, treatment failure cannot be fully explained by poor
drug penetration [1]. Instead, environmental determinants, such as interactions with the host,
can induce phenotypic responses or genetic adaptations in bacteria that reduce antibiotic sen-
sitivity [2,3].
Similarly, within complex polymicrobial communities such as those encountered in chronic
skin infections, burn wound infections, and chronic colonization of the CF lung, inter- and
intraspecies interactions can influence the pathogenicity and antibiotic susceptibility of indi-
vidual organisms [4–6]. The presence of the fungal pathogen Candida albicans, for instance,
can induce S. aureus biofilm formation and thus decrease the bacterium’s susceptibility to anti-
biotic killing [4]. Furthermore, antibiotic deactivation by resistant organisms within a popula-
tion can lead to de facto resistance of all members of the community [7–10].
In such polymicrobial infections, S. aureus is commonly co-isolated with the opportunistic
pathogen P. aeruginosa [11]. These co-infections are generally more virulent and/or more dif-
ficult to treat than infections caused by either pathogen alone [12–14]. The interaction between
these 2 organisms is complex, with P. aeruginosa producing a number of molecules that inter-
fere with S. aureus growth, metabolism, and cellular homeostasis. These molecules include the
secondary metabolites 4-hydroxy-2-heptylquinoline-N-oxide (HQNO), pyocyanin, and
hydrogen cyanide (HCN), all of which inhibit S. aureus respiration [15–17]. Additionally,
P. aeruginosa produces rhamnolipids, biosurfactants that interfere with the S. aureus cell mem-
brane, and an endopeptidase, LasA, that cleaves pentaglycine bridges in S. aureus peptidogly-
can [18–20].
These anti-staphylococcal compounds allow P. aeruginosa to quickly eliminate S. aureus
during in vitro coculture but do not prevent co-colonization in vivo. Recent findings suggest
that within the CF lung, P. aeruginosa strains evolve to be less competitive with S. aureus,
resulting in more stable coinfection of the same spatial niche [21]. Additionally, work by
Antibiotics and interspecies interaction
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Wakeman et al. has shown that the presence of the abundant innate immune protein, calpro-
tectin, induces a phenotypic switch in P. aeruginosa that promotes stable P. aeruginosa and
S. aureus interaction through the chelation of zinc and manganese ions at the site of infection.
This in turn represses P. aeruginosa metabolic toxin production, resulting in significantly less
HQNO and pyocyanin [22]. Similarly, Smith et al. recently demonstrated that S. aureus can
tolerate in vitro coculture with P. aeruginosa in the presence of serum albumin through the
inhibition of P. aeruginosa lasR quorum sensing and thus LasA expression [23]. Despite these
findings, P. aeruginosa LasA, rhamnolipids, HQNO, and pyocyanin are routinely detected at
significant concentrations in burn wounds and in CF sputum samples and thus likely influence
S. aureus physiology [24–28].
We hypothesized that interaction with P. aeruginosa may antagonize or potentiate S. aureus
antibiotic susceptibility and could explain the frequent occurrence of treatment failure in
infections involving otherwise drug-susceptible strains. Furthermore, we hypothesized that
such interactions could be exploited to improve antibiotic treatment outcome. Here we dem-
onstrate that secreted P. aeruginosa factors dramatically alter S. aureus susceptibility to killing
by multiple antibiotic classes, and identify several mediators of S. aureus antibiotic antagonism
or potentiation. Importantly, the production of these molecules is highly strain dependent,
thus implicating the genotype of coinfecting P. aeruginosa strains as critical determinants of
antibiotic treatment outcomes for S. aureus infections. Ultimately, we demonstrate in a mouse
model of S. aureus, P. aeruginosa coinfection that the presence of P. aeruginosa can signifi-
cantly alter the outcome of S. aureus antibiotic treatment. Overall, this work highlights the
importance of considering the microbial context of the infection environment during the
treatment of polymicrobial infection.
Results
P. aeruginosa alters S. aureus susceptibility to antibiotic killing
To investigate the impact of P. aeruginosa on S. aureus antibiotic susceptibility, we measured
the bactericidal activity of 3 antibiotics against S. aureus in the presence of supernatants from
12 P. aeruginosa clinical isolates; 7 from the lungs of CF patients and 5 from burn wounds, as
well as 2 laboratory strains; PAO1 and PA14. We were interested in examining how P. aerugi-
nosa-secreted exoproducts can impact the susceptibility of S. aureus to vancomycin, tobramy-
cin, and ciprofloxacin. Vancomycin is the frontline antibiotic for the treatment of methicillin-
resistant S. aureus (MRSA). Ciprofloxacin and tobramycin are commonly used to treat P. aeru-
ginosa during coinfection.
S. aureus strain HG003 was grown to exponential phase and treated with 500 μL of sterile
supernatant from overnight (18 h) cultures of HG003 (control) or one of the 14 P. aeruginosa
strains prior to antibiotic challenge. After 24 h, cells were washed and plated to enumerate sur-
vivors. We found that the individual bactericidal activities of all 3 antibiotics against S. aureus
were affected by P. aeruginosa supernatants. More specifically, we observed 3 P. aeruginosa iso-
lates that significantly protected S. aureus from killing by tobramycin (BC239, BC312, and
BC252) and one P. aeruginosa isolate (BC310) induced over a 10-fold increase in tobramycin
killing of S. aureus (Fig 1A). We also observed that the majority of P. aeruginosa supernatants
were antagonistic towards ciprofloxacin killing (Fig 1B). Furthermore, supernatants from 8 P.
aeruginosa strains (PAO1, PA14, BC238, BC310, BC249, BC250, BC251, and BC252) dramati-
cally potentiated vancomycin killing of S. aureus, resulting in 100–1,000 times more killing
than the control culture (Fig 1C). These data highlight the variable and strain-dependent influ-
ence of P. aeruginosa on the susceptibility of S. aureus to different antibiotics; however, the
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Fig 1. P. aeruginosa supernatant alters S. aureus antibiotic susceptibility. S. aureus strain HG003 was
grown to mid-exponential phase and exposed to sterile supernatants from S. aureus HG003 (red), P.
aeruginosa laboratory strains PAO1 and PA14 (grey), P. aeruginosa CF clinical isolates (blue) or P.
aeruginosa burn isolates (green) for 30 min prior to addition of (A) 50 μg/ml vancomycin, (B) 58 μg/ml
tobramycin or (C) 2.34 μg/ml ciprofloxacin concentrations similar to the Cmax in humans. An aliquot was
removed after 24 h, washed, and plated to enumerate survivors. The dotted red line represents the number of
survivors in the control culture. All experiments were performed in biological triplicate and the number of
survivors following antibiotic challenge in the presence of P. aeruginosa supernatant was compared to the
HG003 supernatant-treated control. Underlying data can be found in S1 Data. *p<0.05 (one-way ANOVA with
Tukey’s multiple comparisons post-test analysis of surviving CFU). Error bars represent mean + sd. CF, cystic
fibrosis; CFU, colony-forming units.
https://doi.org/10.1371/journal.pbio.2003981.g001
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mechanism(s) by which P. aeruginosa alters S. aureus antibiotic susceptibility remained
unclear.
P. aeruginosa rhamnolipids increase tobramycin uptake and efficacy
against S. aureus
Previous studies have shown that during coculture the presence of P. aeruginosa results in
increased S. aureus resistance to tobramycin through the activity of HQNO [5]. In agreement
with this, we observed that supernatants from BC239 and BC312 and BC252 protected S.
aureus from tobramycin killing (Fig 1A). Paradoxically, however, we observed that the major-
ity of our clinical isolates had no significant impact on tobramycin bactericidal activity. Even
more striking, isolate BC310 appeared to potentiate tobramycin bactericidal activity against S.
aureus (Fig 1A). We hypothesized that the impact of P. aeruginosa on S. aureus tobramycin
susceptibility was multifactorial, with an unidentified factor increasing tobramycin bacteri-
cidal activity.
Tobramycin uptake is dependent on proton-motive force (PMF) [29]. P. aeruginosa
HQNO collapses S. aureus PMF by inhibiting electron transport, thus abolishing tobramycin
uptake into the cell [5]. To explore the possibility that an additional factor within P. aeruginosa
supernatant may influence the bactericidal activity of tobramycin against S. aureus, we exam-
ined S. aureus susceptibility to tobramycin in the presence of supernatant from a PA14
ΔpqsLphzShcnC strain. This strain cannot produce the respiratory toxins HQNO, pyocyanin,
or HCN, all of which inhibit S. aureus respiration and deplete PMF. Strikingly, we found that
PA14 ΔpqsLphzShcnC mutant supernatant led to the rapid eradication of a S. aureus popula-
tion following tobramycin treatment (Fig 2A) (S1A Fig). Heat-inactivation of P. aeruginosa
PA14 supernatant had no impact on its ability to alter tobramycin activity, ruling out heat-
labile proteins as potentiators of tobramycin killing (S1B Fig).
P. aeruginosa produces surfactant molecules called rhamnolipids that inhibit growth of
competing gram-positive bacteria. These amphiphilic molecules increase cell permeability by
interacting with the plasma membrane [30]. We hypothesized that rhamnolipid interaction
with the membrane may facilitate tobramycin entry into otherwise tolerant, PMF-depleted
persister subpopulations. To investigate this possibility, we deleted the rhlA gene in PA14,
which is essential for rhamnolipid biosynthesis. Supernatant from a PA14 ΔrhlA mutant con-
ferred full protection to S. aureus against tobramycin killing (Fig 2A) (S1A Fig). Furthermore,
during tobramycin treatment, the exogenous addition of a 50/50 mix of purified P. aeruginosa
mono- and di-rhamnolipids at 30 μg/ml facilitated the rapid eradication of the S. aureus popu-
lation and decreased the MIC of tobramycin for S. aureus 8-fold (Fig 2A) (S1 Table). This con-
centration is within the physiological range of rhamnolipids likely encountered by S. aureus
during coinfection with P. aeruginosa, as previous work by Bjarnsholt et al. found that clinical
isolates produce a range of 2.4 μg/ml to 72.8 μg/ml rhamnolipids when grown in vitro, and
Read et al. reported rhamnolipid concentrations as high as 64 μg/ml in a CF lung explant
[24,31]. At the concentrations used in this study, rhamnolipids did not display antibacterial
activity in the absence of antibiotic (S1C Fig). Further, incubation with a similar concentration
of L-rhamnose, the glycosyl head constituent of rhamnolipids, had no effect on tobramycin
killing, ruling out metabolite-stimulated PMF generation as the mechanism of tobramycin
potentiation (S1D Fig). Finally, we found that 30 μg/ml purified P. aeruginosa rhamnolipids
led to increased uptake of Texas Red-conjugated tobramycin as determined by flow cytometry
(Fig 2B).
We next measured the relative amount of HQNO and rhamnolipids produced by each P.
aeruginosa isolate using mass spectrometry [32] and a drop-collapse assay, respectively [33].
Antibiotics and interspecies interaction
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Fig 2. P. aeruginosa rhamnolipids potentiate aminoglycoside uptake and cell death in S. aureus. S.
aureus HG003 was grown to mid-exponential phase and exposed to (A) sterile supernatants from P.
aeruginosa or S. aureus or exogenous addition of rhamnolipids (30 μg/ml) before addition of tobramycin
58 μg/ml. At indicated times, an aliquot was washed and plated to enumerate survivors. (B) Texas Red-
conjugated tobramycin was added to S. aureus cultures with or without 30 μg/ml rhamnolipids. Following 1 h,
Texas Red-tobramycin uptake was measured by flow cytometry. (C) Rhamnolipid production present in the
supernatant of P. aeruginosa PAO1, PA14, PA14 ΔrhlA, CF isolates (blue) or burn isolates (green) were
quantified by a drop-collapse assay. Experiments were performed in biological triplicate. Underlying data can
be found in S1 Data. Error bars represent mean ± sd. CF, cystic fibrosis.
https://doi.org/10.1371/journal.pbio.2003981.g002
Antibiotics and interspecies interaction
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We observed a large variance in the production of both HQNO (Table 1) and rhamnolipids
between isolates (Fig 2C). Importantly, the potentiator of tobramycin activity, BC310, was the
only strain shown to be a high rhamnolipid producer without detectable HQNO production.
In contrast, strain BC239, the strongest tobramycin antagonist, was among the highest HQNO
producers, and did not produce rhamnolipids. Together, these data show that P. aeruginosa
has the capacity to both positively and negatively influence S. aureus tobramycin uptake and
bactericidal activity through the action of rhamnolipids and respiratory toxins, respectively.
The presence of these 2 opposing factors may be responsible for the apparent disconnect
between the P. aeruginosa-mediated increase in tobramycin resistance reported previously [5],
and lack of protection from tobramycin killing following treatment with supernatant from the
majority of P. aeruginosa strains observed in this study. Indeed, deletion of either P. aeruginosa
respiratory toxins or rhamnolipids in a P. aeruginosa laboratory strain resulted in supernatants
that facilitate complete sterilization or protection of S. aureus cultures, respectively (Fig 2A).
Furthermore, similar trends were observed when S. aureus MRSA strain JE-2 was challenged
with tobramycin following treatment with P. aeruginosa supernatant, supporting the relevance
of this phenomenon in the clinical treatment of S. aureus infection (S6A Fig).
P. aeruginosa induces multidrug tolerance in S. aureus through
respiratory inhibition
In addition to the ability of HQNO to inhibit uptake of aminoglycosides, we made an interest-
ing and somewhat unexpected observation during our investigation. HQNO production in P.
aeruginosa isolates correlated perfectly with protection against ciprofloxacin killing (Fig 1B)
(Table 1). As ciprofloxacin uptake is PMF-independent, we wondered if P. aeruginosa HQNO
was conferring ciprofloxacin tolerance in S. aureus via an alternate mechanism.
Antibiotic tolerance generally refers to a population-wide decrease in antibiotic susceptibil-
ity, often following exposure to external mediators of bacterial metabolism or physiology. In
contrast, persister cells are generally described as antibiotic-tolerant subpopulations that form
Table 1. LC-MS/MS quantification of HQNO production in P. aeruginosa strains.
Strain Conc. (μM)
PAO1 31.5
PA14 28.3
PA14 ΔpqsL ND
BC236 ND
BC237 18.9
BC238 13.9
BC239 25.7
BC308 ND
BC310 ND
BC312 28.3
BC249 29.0
BC250 28.2
BC251 ND
BC252 47.0
BC253 9.8
Abbreviations: HQNO, 4-hydroxyquinoline N-oxide; LC-MS/MS, liquid chromatography tandem mass
spectrometry. Conc, concentration; ND, not detected.
https://doi.org/10.1371/journal.pbio.2003981.t001
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stochastically in an otherwise susceptible population. We recently demonstrated that both phe-
nomena are specifically associated with cells entering a low ATP state [34,35]. Subpopulations
of low energy cells give rise to persisters, while changes in the environment can lead to a low
energy antibiotic-tolerant state in the entire population. HQNO inhibits respiration, the most
efficient mechanism for ATP generation in S. aureus. We hypothesized that P. aeruginosa inhi-
bition of S. aureus respiration induces a low ATP, multidrug-tolerant state of the entire popu-
lation. In support of this, no protection from antibiotic killing was observed following pre-
treatment with PA14 supernatant during anoxic growth (S2A Fig). We then cloned the fer-
mentation-specific promoter for pyruvate acetyltransferase (pflB) from S. aureus upstream of
gfp in a low-copy plasmid. Expression of pflB only occurs under anaerobic conditions or when
respiration is inhibited [36]. We found that transcription of the pflB promoter was activated
in response to supernatant from all of the P. aeruginosa strains with the exception of PA14
ΔpqsLphzShcnC (negative control) and 4 of the clinical isolates, BC236, BC308, BC310, and
BC251. Importantly, these were the only clinical isolates that did not induce significant protec-
tion from ciprofloxacin killing (Fig 1B). Activation of pflB during aerobic growth demonstrates
that respiration is inhibited in these conditions (Fig 3A). Direct intracellular ATP quantifica-
tion of cultures treated with P. aeruginosa or S. aureus supernatant revealed that P. aeruginosa
supernatant induces significant depletion of S. aureus intracellular ATP (Fig 3B).
Fig 3. P. aeruginosa secondary metabolites inhibit S. aureus aerobic respiration resulting in a drop in intracellular ATP and protection
from ciprofloxacin killing. (A) S. aureus strain HG003 harboring plasmid PpflB::gfp was grown to mid-exponential phase and treated with
supernatant from P. aeruginosa PAO1, PA14, CF isolates (blue) or burn isolates (green), for 30 min. OD600 and gfp expression levels were
determined after 16 h using a Biotek Synergy H1 microplate reader. (B) Intracellular ATP was measured after 1.5 h incubation with supernatant.
***p < 0.0005 (one-way ANOVA with Tukey’s multiple comparison post-test). (C) S. aureus strain HG003 was grown to mid-exponential phase
in MHB media and pre-treated with sterile supernatants from P. aeruginosa strains PA14 wild-type or its isogenic mutants or (D) physiologically-
relevant concentrations of HQNO, PYO, or NaCN for 30 min prior to antibiotic challenge [26,27]. At indicated times, an aliquot was washed and
plated to enumerate survivors. All experiments were performed in biological triplicate. Underlying data can be found in S1 Data. Error bars
represent mean ± sd. CF, cystic fibrosis; CFU, colony-forming units; GFP, green fluorescent protein; HQNO, 4-hydroxyquinoline N-oxide; MHB,
Mueller-Hinton broth; NaCN, sodium cyanide; OD, optical density; PYO, pyocyanin.
https://doi.org/10.1371/journal.pbio.2003981.g003
Antibiotics and interspecies interaction
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We found that mutation of pqsL (HQNO negative) drastically reduced the capacity of PA14
supernatant to protect S. aureus from ciprofloxacin killing, suggesting tolerance to ciprofloxa-
cin killing is mediated by HQNO (Fig 3C). Individually, mutations to the biosynthetic path-
ways for pyocyanin (phzS) and hydrogen cyanide (hcnC) had no influence on P. aeruginosa-
conferred protection from ciprofloxacin killing. However, supernatants from a ΔpqsLphzS and
a respiratory toxin-null mutant (ΔpqsLphzShcnC) were further reduced in their capacity to
protect S. aureus from ciprofloxacin killing (S2B Fig) (Fig 3C). Together, these data demon-
strate that P. aeruginosa confers protection from ciprofloxacin killing to S. aureus through res-
piration inhibition and depletion of ATP. Further, treatment with HQNO, pyocyanin, and
HCN at concentrations detected within the sputum of CF patients with active P. aeruginosa
infection [26,27,37] induced tolerance of S. aureus to ciprofloxacin (Fig 3D). Surprisingly, sim-
ilar levels of tolerance were observed for other classes of antibiotics including tobramycin and
vancomycin, with HQNO inducing the most robust tolerance to antibiotic killing (S2C and
S2D Fig).
P. aeruginosa LasA endopeptidase potentiates vancomycin bactericidal
activity against S. aureus
The presence of purified HQNO protects S. aureus from vancomycin killing (S2D Fig). How-
ever, P. aeruginosa supernatant from the majority of isolates tested significantly potentiated
vancomycin killing of S. aureus (Fig 1C). We hypothesized that, similar to what was observed
with S. aureus susceptibility to tobramycin, an additional factor present in P. aeruginosa super-
natant is capable of overcoming the protective effects of HQNO to potentiate vancomycin
killing of S. aureus. Heat denaturation of PAO1 supernatant completely abrogated the potenti-
ating effect, suggesting the involvement of heat-labile extracellular protein(s) in the phenotype
(Fig 4A). Bacteriolytic assays revealed that the PAO1 supernatant combined with vancomycin-
induced dramatic lysis of the population that was absent in the presence of either factor alone
(Fig 4B). This led us to examine the potential role of the P. aeruginosa extracellular lytic
enzyme, LasA, in mediating vancomycin killing. LasA cleaves pentaglycine cross bridges in S.
aureus peptidoglycan and has been shown to attack the cell wall of S. aureus during in vivo
competition [18]. We examined the capacity of supernatant from a PAO1 lasA mutant to
potentiate vancomycin killing. The lasA mutant supernatant did not potentiate killing by van-
comycin compared to a 3-log reduction in S. aureus cfu in the presence of the PAO1 wild-type
supernatant (Fig 4A) (S4A Fig). Similar trends were observed in a S. aureus MRSA strain JE-2
(S6B Fig). As it was previously shown that S. aureus can degrade HQNO [38], the absence of
which could result in a more dramatic LasA-dependent potentiation effect in our supernatant
experiments, we examined vancomycin killing in a coculture model where P. aeruginosa is
present to continually produce HQNO. Again, we found that the presence of wild-type PAO1
resulted in a 3-Log reduction in cfu following vancomycin challenge, and that this potentiation
was not observed in the presence of a PAO1 lasA mutant, where we observed 100-fold more
survivors at 24 h (S7 Fig).
Next, we measured the levels of LasA in the supernatants of each clinical isolate via western
blot and an additional assay developed previously to quantify LasA activity [39] (Fig 4C).
Seven of the clinical isolates and both laboratory strains were positive for LasA. Of these, only
BC253, the lowest LasA producer, and BC312, a high HQNO producer, did not induce at least
a 10-fold increase in killing by vancomycin (Fig 1C). Of the 5 LasA negative strains, only one,
BC251, significantly potentiated vancomycin killing, although no lysis of the culture was
observed (S4B Fig). These data suggest that P. aeruginosa potentiates the vancomycin killing of
S. aureus via at least 2 distinct mechanisms, only one of which is LasA-dependent.
Antibiotics and interspecies interaction
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Fig 4. P. aeruginosa supernatant potentiates killing by vancomycin via the LasA endopeptidase. S.
aureus HG003 was grown to mid-exponential phase and exposed to sterile supernatants for 30 min prior to
addition of vancomycin 50 μg/ml. Where indicated, PAO1 supernatant was heat inactivated at 95˚C for 10
min. (A) At indicated times, an aliquot was removed, washed, and plated to enumerate survivors or (B) 100 μl
cells were added to a 96-well plate and lysis was measured at OD600 every hour for 16 h. (C) LasA present in
the supernatant of P. aeruginosa PAO1, PA14, CF isolates (blue) or burn isolates (green) was quantified by
western blot and the ability of each supernatant to lyse heat-killed S. aureus HG003 cells after 2 h. All
experiments were performed in biological triplicate. Underlying data can be found in S1 Data. Error bars
represent mean ± sd. CF, cystic fibrosis.
https://doi.org/10.1371/journal.pbio.2003981.g004
Antibiotics and interspecies interaction
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P. aeruginosa potentiates vancomycin killing in a mouse model of P.
aeruginosa/S. aureus coinfection
Our observation that purified HQNO induces multidrug tolerance in S. aureus agrees with
recent findings that P. aeruginosa protects S. aureus biofilm from vancomycin killing [40].
However, we have demonstrated that under planktonic growth conditions the protective
effects of P. aeruginosa HQNO on S. aureus vancomycin susceptibility (S2D Fig) can be over-
come by the lytic activity of LasA to potentiate vancomycin killing. In order to determine
whether the protective effects of HQNO or the potentiating effects of LasA predominated in
vivo, we adapted a previously described murine model of burn injury for S. aureus and P. aeru-
ginosa coinfection [41]. Briefly, groups of mice were inflicted with a 20% total body surface
area burn, then after 24 h were infected subcutaneously at the wound site with approximately
105 CFU S. aureus, HG003 alone, or in combination with 103 PAO1 or 103 PAO1 lasA::tet.
Mice were then treated daily with vancomycin and harvested 72h post infection.
LasA has been shown to mediate P. aeruginosa epithelial cell invasion and has been shown
to be essential for corneal infections [42,43]. Interestingly, in our burn model, it appeared that
the presence of PAO1 resulted in a higher burden of S. aureus, which is also dependent on
lasA. However, for this study, we were interested solely on the impact of PAO1 presence on
vancomycin sensitivity of S. aureus. While we observed no significant vancomycin efficacy in
S. aureus mono-infected mice, relative to an untreated control group, we observed a 2-Log
reduction in S. aureus burden following vancomycin treatment in mice coinfected with P. aer-
uginosa PAO1 (Fig 5A and 5B). Furthermore, no potentiation of vancomycin killing was
observed in mice coinfected with the PAO1 lasA transposon mutant (Fig 5A and 5B). Impor-
tantly, P. aeruginosa appeared to be unaffected by vancomycin treatment, and burden was sim-
ilar for both wild type and PAO1 lasA::tet-infected mice (S8 Fig). Finally, we observed that
PAO1 transcription of lasA is strongly up-regulated (approximately 200-fold) during in vivo
coinfection (Fig 5C). Up-regulation of lasA transcription was also observed during P. aerugi-
nosa monoinfection, suggesting that lasA expression is independent of the presence or absence
of S. aureus during burn wound infection.
Together, these data demonstrate that the presence of P. aeruginosa can potentiate vanco-
mycin killing of S. aureus during infection through the production of LasA. To our knowledge,
these data represent the first evidence of P. aeruginosa altering S. aureus antibiotic susceptibil-
ity in vivo and underlines the importance of deciphering interspecies interactions to improve
the antibiotic treatment of polymicrobial infections.
Discussion
Polymicrobial infections are associated with exacerbated morbidity, accelerated disease pro-
gression and poor treatment outcome [44–47]. Antibiotic therapies are often selected to specif-
ically target individual pathogens within a polymicrobial community without consideration of
how interspecies interactions may alter a target organism’s antibiotic susceptibility. S. aureus
and P. aeruginosa are 2 major human pathogens that frequently coexist within chronically col-
onized patients, and these infections are often impossible to resolve through conventional anti-
biotic therapy. We find that P. aeruginosa dramatically alters the susceptibility of S. aureus to
the killing activities of commonly used and clinically relevant antibiotics through 3 distinct
pathways governed by rhamnolipids, HQNO, and LasA, and that these molecules are pro-
duced at different levels by P. aeruginosa clinical isolates resulting in vastly different impacts
on antibiotic efficacy against S. aureus (Fig 6; summarized in S2 Table). We found that P. aeru-
ginosa staphylolytic activity correlates with vancomycin potentiation, and that P. aeruginosa
HQNO production correlates with ciprofloxacin antagonism (S9A and S9B Fig). Correlation
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analysis with rhamnolipid production is not appropriate as the measurement of biosurfactant
activity is qualitative. Overall, our results imply that antibiotic efficacy is strongly influenced
by interactions between bacterial species, which may have major implications for future sus-
ceptibility determination and antibiotic treatment of polymicrobial infection.
Fig 5. P. aeruginosa potentiates vancomycin killing of S. aureus in a murine model of coinfection. Approximately 1
x 105 CFU S. aureus strain HG003 was administered subcutaneously alone or in combination with approximately 1 x 103
CFU P. aeruginosa PAO1 or PAO1 lasA::tn 24 h after burn. Mice were left untreated or administered 110 mg/kg
vancomycin subcutaneously once daily for 2 d. Mice were sacrificed 48 h post infection. (A) Tissue biopsies at the site of
infection were harvested and homogenized and S. aureus burdens were enumerated on selective media. Data for each
group are compiled from 2 independent experiments. (n = 6–10 mice per group) *p < 0.05, ***p < 0.005 (Mann-Whitney
test). (B) Relative percentage survival for HG003 in each condition was calculated by dividing the CFU/g tissue of mice
treated with vancomycin by the average CFU/g tissue of untreated mice. Maximum percentage survival is 100%. Data for
each group are compiled from 2 independent experiments. (C) Expression of lasA in tissue from mono- (PAO1 alone) and
coinfected (PAO1/HG003) mice relative to the starting inoculum measured by qRT-PCR. Underlying data can be found in
S1 Data. *p < 0.05 (Student t test). Error bars represent mean + sd. CFU, colony-forming units; ctr, control; qRT-PCR,
quantitative reverse transcription PCR; vanc, vancomycin; WT, wild-type.
https://doi.org/10.1371/journal.pbio.2003981.g005
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Aminoglycosides are used routinely for the treatment of P. aeruginosa infection. Though
aminoglycosides are effective against susceptible populations of S. aureus, bactericidal activity
is limited against anaerobic, small colony variant (SCV), biofilm-associated, or persister sub-
populations due in part to decreased respiration and thus PMF-dependent drug uptake
[48,49]. Stimulating tobramycin uptake has been proposed as a way to eradicate these recalci-
trant populations [49]. We have observed that P. aeruginosa-produced rhamnolipids sensitize
the entire S. aureus population to tobramycin killing, leading to total eradication of otherwise
tolerant populations. P. aeruginosa rhamnolipids may represent a promising new avenue for
potentiating aminoglycoside killing of recalcitrant S. aureus and possibly other bacterial popu-
lations. Interestingly, a recent study has revealed that S. aureus increases tobramycin resistance
in P. aeruginosa in an in vitro biofilm model, further emphasizing the importance of interac-
tion between these organisms in dictating aminoglycoside susceptibility [50].
Vancomycin is a frontline antibiotic in the treatment of MRSA. To exert bactericidal activ-
ity against S. aureus, vancomycin must specifically bind the D-Ala-D-Ala residues of lipid II
during cell wall biosynthesis [51]. However, vancomycin will also bind D-Ala-D-Ala residues
of mature peptidoglycan. Thus, vancomycin exhibits limited bactericidal activity against dense
populations of S. aureus cells due to the increased number of “decoy” targets available in late
Fig 6. P. aeruginosa-mediated alteration of S. aureus antibiotic susceptibility. P. aeruginosa exoproducts PYO, HQNO, and HCN inhibit S.
aureus electron transport, leading to collapse of PMF and inhibition of the F1F0 ATPase leading to a decrease in S. aureus antibiotic susceptibility.
Conversely, P. aeruginosa RLs intercalate into the plasma membrane-forming pores that permit aminoglycoside entry into the cell in a PMF-
independent manner, while P. aeruginosa endopeptidase LasA cleaves pentaglycine crosslinks between peptidoglycan molecules of the cell wall,
increasing vancomycin-mediated lysis of S. aureus. HCN, hydrogen cyanide; HQNO, 2-heptyl-4-hydroxyquinoline N-oxide; NAG, N-acetylglucosamine;
NAM, N-acetylmuramic acid; PMF, proton-motive force; PYO, pyocyanin; RL, rhamnolipids.
https://doi.org/10.1371/journal.pbio.2003981.g006
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exponential or stationary phase populations of cells. Our data demonstrate that through LasA,
P. aeruginosa can restore vancomycin efficacy against otherwise tolerant S. aureus populations.
In support of this, we found that strains capable of increasing vancomycin lysis of S. aureus
were LasA producers while the inert strains, generally, were not. This variance in LasA produc-
tion may be due to mutations in lasR, an activator of lasA expression, which acquires muta-
tions at high frequency during chronic P. aeruginosa infection [52]. We hypothesize that the
combined action of cell wall degradation by LasA and inhibition of de novo peptidoglycan bio-
synthesis by vancomycin leads to cell wall destruction and a potent bactericidal effect.
P. aeruginosa HQNO induces tolerance of S. aureus to multiple antibiotic classes through
respiration inhibition and depletion of intracellular ATP. Recent work by Orazi et al. found
that in a bronchial epithelial tissue culture system, P. aeruginosa inhibited the killing activity of
vancomycin through HQNO [40]. In agreement with these findings, we observed that the
addition of exogenous HQNO protects S. aureus from vancomycin killing (S2D Fig) However,
during planktonic growth the protective effect of HQNO was overshadowed by LasA-medi-
ated potentiation of vancomycin killing. We were interested in examining whether P. aerugi-
nosa antagonized or potentiated vancomycin in vivo, and found that P. aeruginosa expresses
LasA at high levels during infection, and significantly potentiates the activity of vancomycin
against S. aureus. This effect was abrogated in a P. aeruginosa lasA mutant suggesting that
LasA plays a role in potentiating vancomycin killing of S. aureus during polymicrobial
infection.
Similarly, we observed in vitro that P. aeruginosa-produced rhamnolipids can negate the
protective effect of HQNO to restore or even increase S. aureus susceptibility to tobramycin
killing. The opposing influences of HQNO and rhamnolipids on aminoglycoside activity
against S. aureus may have major implications for aminoglycoside treatment of S. aureus dur-
ing coinfection where production of one factor may dominate, leading to inhibition or poten-
tiation of tobramycin activity against S. aureus. Indeed, we observed that clinical isolates
produce a range of HQNO, LasA, and rhamnolipids, and production of each factor determines
an isolate’s ability to potentiate or antagonize antibiotic killing.
P. aeruginosa strain variation and the impact of this variation on S. aureus antibiotic suscep-
tibility suggests that a personalized approach to antibiotic therapy may be necessary to identify
the ideal therapy to eradicate infection in an individual patient based on the genotype of S.
aureus and the genotype of the bacteria it’s interacting with. Recent work has demonstrated
that within the infectious environment, the production of HQNO, LasA, and rhamnolipids is
highly variable. P. aeruginosa isolates from chronic CF infections frequently harbor mutations
associated with decreased quorum-sensing activities and increased alginate production [52].
These mutations are attributed to the conversion to a mucoidal phenotype of P. aeruginosa
that is significantly less competitive with S. aureus [53]. P. aeruginosa mucoidy is rarely associ-
ated with acute infection, thus the impact of P. aeruginosa on antibiotic susceptibility of S.
aureus may differ during acute versus chronic coinfection. Future studies are necessary to
identify genetic hallmarks of P. aeruginosa strains that potentiate or antagonize the activities of
different antibiotic classes against S. aureus towards the goal of improving antibiotic efficacy
against currently unresolvable coinfections.
It has long been observed that S. aureus is the dominant pathogen in the early life of CF
patients with P. aeruginosa eventually dominating later in life [54]. It is interesting to consider
a possible role of altered antibiotic susceptibility of S. aureus contributing to these dynamics,
where vancomycin or tobramycin treatment in the presence of LasA- or rhamnolipid-produc-
ing P. aeruginosa strains may be particularly efficacious, resulting in a decrease in relative S.
aureus abundance.
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In summary, we characterized 3 distinct P. aeruginosa-mediated pathways altering S. aureus
antibiotic susceptibility. HQNO induces a low-energy multidrug-tolerant state while LasA
and rhamnolipids overcome this tolerance in cooperation with vancomycin and tobramycin,
respectively. Exploitation of these newly discovered pathways may lead to better prediction of
antibiotic efficacy in vivo and improved treatments for chronic S. aureus infection.
Materials and methods
Ethics statement
P. aeruginosa CF isolates were provided by an IRB-approved biospecimen bank (IRB#02–
0948). P. aeruginosa burn wound isolates were from a previous study and use was deemed
exempt by IRB study number #17–0836. All mice used in the study were maintained under
specific pathogen-free conditions in the Animal Association of Laboratory Animal Care-
accredited University of North Carolina Department of Laboratory Animal Medicine Facili-
ties. All protocols were approved by the Institutional Animal Care and Use Committee at the
University of North Carolina, protocol number 17–141, and all experiments were performed
in accordance with the National Institutes of Health. Animals were anesthetized by inhalation
of vaporized isoflurane. A subcutaneous injection of morphine was given prior to burn injury
for pain control, and an intraperitoneal injection of lactated Ringer’s solution was given imme-
diately after burn injury for fluid resuscitation. Animals were provided morphinated water ab
libitum and monitored twice a day.
Bacterial strains and growth conditions
S. aureus strains HG003 and JE-2 were cultured aerobically in Mueller-Hinton broth (MHB)
at 37˚C with shaking at 225 rpm. HG003 is a well-characterized model strain of S. aureus,
while JE-2 is a well-characterized USA300 S. aureus associated with community-acquired
MRSA infection. For anaerobic growth, overnight cultures were washed twice with PBS and
diluted into 5 ml of pre-warmed (37˚C) TSB + 100 mM MOPS (pH7) to an OD600 of 0.05. Cul-
tures were prepared in triplicate in 16 x 150 mm glass tubes containing 1 mm stir bars. Follow-
ing dilution, cultures were immediately transferred into a Coy anaerobic chamber and grown
at 37˚C with stirring. P. aeruginosa strains were grown aerobically in MHB at 37˚C with shak-
ing at 225 rpm. Burn wound isolates represent the first positive Pseudomonal wound cultures
obtained from 5 unique patients admitted to the NC Jaycee Burn Center between Nov 2015
and April 2016 with a total body surface area burn 20% and/or inhalational injury after
obtaining informed consent. CF isolates were collected from 5 patients at the UNC medical
center. Isolates were cultured from sputum or bronchoalveolar lavage (BAL) from patients
with CF after obtaining informed consent. All burn and CF isolates were grown on Pseudomo-
nas isolation agar (BD Difco) and verified with 16S ribosomal sequencing using the primer
pair 5’-AGTATTGAACTGAAGAGTTTGATCATGG-3’ and 5’-CTGAGATCTTCGATTAAG
GAGGTGA-3’ for PCR amplification.
Strain construction
The PAO1 lasA mutant (PW4282 lasA-H03::ISlacZ/hah) was from the PAO1 knockout
library [55]. PA14 deletion mutants were constructed by singly or sequentially deleting the
coding sequences of rhlA, pqsL, phzS, and hcnC. Briefly, flanking primers were designed to
anneal 800–1,200 bp upstream and downstream of the coding region. The resulting PCR
product was inserted into plasmid pEX18Gm in accordance with the NEBuilder HiFi DNA
Assembly protocol (New England Biolabs). Mutant alleles were integrated onto the
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chromosome of PA14 as described previously [56]. Briefly, pEX18Gm containing the in-
frame deletion and gene-specific flanking regions was mated into P. aeruginosa via Escheri-
chia coli S17-λpir. Primary integrants were selected for with gentamycin and irgasan, then
grown for 4 h in LB without selection to allow for recombination. Dilutions of P. aeruginosa
were plated on LB containing 8% sucrose for counterselection (loss of plasmid). Deletion
strains were confirmed through PCR and sequencing (Genewiz). Plasmid PpflB::gfpwas con-
structed as follows, 298 bp upstream of the pflB coding region was amplified from HG003
genomic DNA using primers flanked with EcoRI and XbaI sites and cloned upstream of
gfpuvr in plasmid pALC1434 [57].
Antibiotic survival assays
To prepare sterile supernatants, S. aureus and P. aeruginosa strains were grown in MHB at
37˚C with shaking at 225 rpm for approximately 20 h. The cultures were pelleted and superna-
tants were passed through a 0.2 μm filter. HG003 or JE-2 was grown to approximately 5 x 107
(for cell wall acting antibiotics) or approximately 2 x 108 cfu/ml (for all other antibiotics) in 3
ml MHB under aerobic or in 5 ml TSB + 100 mM MOPS under anaerobic conditions. Cells
were pre-treated with 0.5 ml sterile supernatant (or 0.83 ml for anaerobic cultures) and
returned to the incubator for a further 30 min. A 30-min pre-exposure was routinely used as
we attempted to emulate the situation in vivo, where a population that has encountered and
reacted to the relevant metabolites is subsequently exposed to antibiotic treatment. Where
appropriate, cells were treated with 0.5 ml of P. aeruginosa culture taken directly from station-
ary phase (18 h) cultures in place of sterile supernatant. Coculture experiments were per-
formed in the presence of 5% bovine serum albumin (BSA) to facilitate S. aureus/P. aeruginosa
coexistence. An aliquot was plated to enumerate cfu before the addition of antibiotics. Antibi-
otics were added at concentrations similar to the Cmax in humans at recommended dosing;
ciprofloxacin 2.34 μg/ml [58], tobramycin 58 μg/ml [59], vancomycin 50 μg/ml [60]. The
Cmax of vancomycin is physiologically relevant for bacteremia and infections with good blood
supply. The Cmax of vancomycin in serum is likely higher than that reached in the lung during
IV infusion, however, it is certainly within the range experienced during inhaled therapy
where clinical trials observed a Cmax of 270 μg/ml in sputum of CF patients. The Cmax of
tobramycin is 58 μg/ml. Regarding lung concentrations, work by Ruddy et al. has found that
inhaled tobramycin therapy results in sputum concentrations of between 17.2 and 327.3 μg/
ml. The concentration we use is well within this range. Also, this therapy fails to eradicate P.
aeruginosa in vivo and thus, we believe, is physiologically relevant for this study [61]. The cip-
rofloxacin blood Cmax used in this study is 2.34 μg/ml. This is also well within the physiologi-
cally relevant concentration for lung infection where ciprofloxacin concentration is actually
higher than corresponding blood serum levels [62].
Ciprofloxacin concentration was increased to 4.68 μg/ml when cells were grown in TSB +
100 mM MOPS to account for any decrease in pH where ciprofloxacin killing activity is
reduced. At indicated times, an aliquot was removed and washed with 1% NaCl. Cells were
serially diluted and plated to enumerate survivors. We routinely used 2 time points to enumer-
ate survivors, 16 h and 24 h after antibiotic challenge as we previously found that, in S. aureus,
susceptible cells are killed and a stable subpopulation of survivors emerges between 16 and 24
h of exposure to antibiotics [35,63]. Where indicated sterile supernatant was heat-inactivated
at 95˚C for 10 min before addition to culture. Where indicated, pyocyanin 100 μM, HQNO
11.5 μM, sodium cyanide 150 μM, or rhamnolipids 10–50 μg/ml (50/50 mix of mono- and di-
rhamnolipids, Sigma) or L-rhamnose 10–50 μg/ml were added in place of supernatant. Con-
centrations of respiratory toxins represent levels detected in the sputum of CF patients [26,27].
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Promoter induction measurement
S. aureus strain HG003 harboring gfppromoter plasmid PpflB::gfpwas grown to approximately
2 x 108 cfu/ml in 3 ml MHB containing chloramphenicol 10 μg/ml. Cultures were treated with
0.5 ml supernatant from HG003, PAO1, PA14, or P. aeruginosa clinical isolates as indicated.
200 μl culture was added to the wells of a clear bottom, black side 96-well plate. The plate was
placed in a Biotek Synergy H1 microplate reader at 37˚C with shaking. Absorbance (OD600)
and GFP fluorescence (emission 528 nm and excitation 485 nm) were measured every 1 h for
16 h. GFP values were divided by OD600.
ATP assays
HG003 was grown to approximately 2 x 108 cfu/ml in 3 ml MHB and pre-treated with 0.5 ml
sterile supernatant from S. aureus HG003 or P. aeruginosa PAO1 or PA14. ATP levels of the
cultures were measured after 1.5 h, as described previously using a Promega BacTiter Glo kit
according to the manufacturer’s instructions [35]. P-values are indicated.
Vancomycin lysis assay
HG003 was grown to approximately 2 x 108 cfu/ml in 3 ml MHB and pre-treated with 0.5 ml
sterile supernatant from S. aureus HG003, P. aeruginosa PAO1, PA14, or P. aeruginosa clinical
isolates as indicated. Cells were incubated for a further 30 min before addition of vancomycin
50 μg/ml. 200 μl aliquots were added to the wells of a clear 96-well plate and placed in a Biotek
Synergy H1 microplate reader. Absorbance (OD600) was measured every 1 h for 16 h.
Western blot analysis of LasA
P. aeruginosa strains were grown in MHB media for ~ 20 h. Cultures were normalized to
OD600 2.0 and pelleted, and supernatants were passed through a 0.2 μm filter. Supernatants
were boiled in SDS-sample buffer and run on a 4%–12% bis-tris acrylamide gel (Invitrogen).
Protein was transferred onto a PVDF membrane, and LasA was detected using rabbit poly-
clonal anti-LasA antibodies (LifeSpan BioSciences, Inc.).
Staphylolytic assay
Staphylolytic assay was modified from Grande et al. [39]. Briefly, stationary phase S. aureus
strain HG003 was heat killed at 95˚C for 20 min. Cells were pelleted and resuspended in 20
mM Tris-HCl (pH 8.0) at an OD595 0.8–1. P. aeruginosa strains were cultured in MHB media
for approximately 20 h. Cultures were normalized to OD600 2.0, pelleted and supernatants
were passed through a 0.2 μm filter. Seventeen microliters of sterile supernatant were added to
a 100 μl heat-killed cells. OD595 was measured at time 0 and after 2 h, and percent cell lysis was
determined. The values shown represent the average of biological triplicates.
Tobramycin-Texas Red uptake
Tobramycin-Texas Red was made as described previously [64,65]. S. aureus strain HG003 was
grown to mid-exponential phase and then incubated with or without 30 μg/ml rhamnolipids
for 30 min. Cells were plated to enumerate cfu prior to addition of Texas-Red tobramycin at a
final concentration of 58 μg/ml. After 1 h, an aliquot of cells was removed, washed twice in 1%
NaCl, and plated to enumerate survivors. The remaining aliquot was analyzed for Texas Red
uptake on a BD Fortessa flow cytometer. Thirty thousand events were recorded. Figures were
generated using FSC Express 6 Flow.
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Rhamnolipid quantification
P. aeruginosa rhamnolipid production was quantified utilizing a drop collapse assay, as previ-
ously described [33]. Briefly, clarified supernatants from overnight cultures of P. aeruginosa
strains were serially diluted (1:1) with deionized water plus 0.005% crystal violet for visualiza-
tion. Twenty-five microliters of aliquots of each dilution were spotted on to the underside of a
petri dish plate and tilted to a 90˚ angle. Surfactant scores represent the reciprocal of the high-
est dilution at which a collapsed drop migrated down the surface of the plate.
LC-MS/MS quantification of HQNO
Five hundred microliters of aliquots of P. aeruginosa supernatant were extracted 3 times with 1
ml of ethyl acetate containing 0.01% acetic acid. For each extraction, samples were vortexed
for 30 s then centrifuged at 15,000 xg for 2 min. The organic phases were removed and com-
bined in a separate tube and evaporated to dryness in a TurboVap under a gentle stream of
nitrogen at 50˚C. Dried samples were reconstituted in 250 μl acetonitrile and a portion diluted
by a factor of 100 prior to analysis by liquid chromatography tandem mass spectrometry
(LC-MS/MS). Quantitative analyses were performed on a Quantum Ultra triple quadrupole
mass spectrometer (Thermo Scientific, Waltham, MA) equipped with an Acquity ultra-perfor-
mance liquid chromatography (UPLC) system (Waters Corp., Milford, MA). A sample injec-
tion volume of 10 μl was separated on a 2.1 x 100 mm, 1.7 μm, CSH Fluoro-Phenyl UPLC
column (Waters Corp., Milford, MA) at a flow rate of 250 μl per minute and a column temper-
ature of 40˚C. Mobile phase solvents consisted of 0.1% acetic acid in deionized water (A) and
methanol (B). Separation was achieved with a linear gradient from 30% to 95% B over 5 min
with a total run time of 10 min. Column effluent was diverted to waste from 1–3 and 7–10
min, and HQNO eluted at a retention time of 5.8 min. The mass spectrometer was operated in
positive ion electrospray mode (3,000 V; 250˚C), and data were acquired by selected reaction
monitoring (SRM) in centroid mode using a mass transition of 260.1 to 159.3 m/z and a colli-
sion energy of 26 eV.
Burn wound model of P. aeruginosa/S. aureus coinfection
Animals were purchased from Taconic Farms and housed in specific pathogen-free conditions
in the Animal Association of Laboratory Animal Care at the University of North Carolina’s
Department of Laboratory Animal Medicine Facilities. All protocols were approved by the
Institutional Animal Care and Use Committee at the University of North Carolina, and all
experiments were performed in accordance with the National Institutes of Health. Wild type
C57BL/6 mice were burned and infected as previously described [41]. Briefly, a 65 g copper
rod was heated to 100˚C and used to create a full-contact burn of approximately 20% of total
body surface area through 4 applications of the rod to the anesthetized animal’s dorsal region.
In preparing the inoculum, overnight cultures of bacterial strains were subcultured into fresh
MHB and grown for 2.5 h to mid-exponential phase. An aliquot of each culture was centri-
fuged and washed with 1 ml of PBS + 1% protease peptone. Approximate bacterial density was
calculated by absorbance (OD600), and cultures were diluted to obtain the desired concentra-
tion. Inoculum was verified through CFU enumeration. Mice were infected subcutaneously in
the mid-dorsal region in unburned skin surrounded by the wound 2 4h after burn. Mice were
administered vancomycin intraperitoneally at 110 mg/kg once daily for 2 d, then sacrificed 48
h post infection. At the time of sacrifice, 5 mm tissue biopsy of the bacterial infection site were
aseptically removed, homogenized with 3.2 mm stainless steel beads and a Bullet Blender
(Next Advance; Averill Park, NY), then bacterial burden was enumerated by plating serial
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dilutions of the homogenates on selective media. Mice that mostly cleared P. aeruginosa (<103
CFU/g tissue) were discounted from analysis.
qRT-PCR
Two hundred and fifty microliters of homogenized tissue were suspended in 1 ml of Trizol
(ThermoFisher) and frozen at −80˚C until extraction. RNA was extracted following manufac-
turer’s protocol. Extracted RNA was DNase treated with 10 units RQ-1 RNase free DNase
(Promega) following manufacturer’s protocol. RNA was purified after DNase treatment using
RNA Clean and Concentrator-25 (Zymo) and eluted in 30 μl of H2O, and quantified using a
NanoDrop spectrophotometer. Five hundred nanograms of total RNA were used to generate
cDNA using SuperScript II Reverse Transcriptase (ThermoFisher) and Random Primer 9
(NEB) following manufacturer’s protocol. Copy number of lasA and gyrAwere quantified
using iTaq Universal Sybr Green master mix (Bio-Rad) in 20 ul reaction volumes on a Roche
LightCycler 96, using the following primer pairs: lasA_RT_5 5’-CCTGTTCCTCTACGGTCG
CG-3’, lasA_RT_3 5’-GGTTGATGCTGTAGTAGCCG-3’, gyrA_5_RT 5’-GAAGCTGCTCTC
CGAATACC-3’, gyrA_3_RT 5’-CAGTTCCTCACGGATCACCT-3’.
MIC assays
MICs were determined using the microdilution method. Briefly, approximately 5 x 105 cfu
were incubated with varying concentrations of ciprofloxacin, tobramycin, or vancomycin in a
total volume of 200 μl MHB in a 96-well plate. Where indicated, 34 μl MHB was replaced with
sterile P. aeruginosa or S. aureus supernatant or purified HQNO or rhamnolipids at final con-
centrations of 11.5 μM and 30 μg/ml, respectively. MICs were determined following incuba-
tion at 37˚C for 24 h.
Statistical analysis
Statistical data analysis was performed using Prism GraphPad software (San Diego, CA) ver-
sion 5.0 b. Differences in S. aureus intracellular ATP concentration or surviving S. aureus CFU
following P. aeruginosa supernatant treatment and antibiotic challenge were compared using a
one-way ANOVA with Tukey’s multiple comparisons post test or the Student t test where
appropriate. Differences in tissue burden following S. aureus and P. aeruginosa coinfection
were compared with a Mann-Whitney test. Finally, the statistical significance of each correla-
tion analysis was determined with a two-tailed Pearson’s chi-squared test. Differences with a
p-value 0.05 were considered significant.
Supporting information
S1 Table. MICs of S. aureus HG003. MIC, minimum inhibitory concentration.
(DOCX)
S2 Table. Summary of P. aeruginosa isolate phenotypes and resulting effect on HG003 sus-
ceptibility to listed antibiotics.
(DOCX)
S1 Data. Excel spreadsheet containing underlying data for Figs 1–5 and S1–S8 Figs.
(XLSX)
S1 Fig. Rhamnolipids do not cause cell death in S. aureus in the absence of tobramycin.
S. aureus strain HG003 was grown to mid-exponential phase in MHB media and pre-treated
with (A,B) sterile supernatants from P. aeruginosa PA14 wild type or isogenic mutants,
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S. aureus HG003 or (D) L-rhamnose 10–50 μg/ml before addition of tobramycin at 58 μg/ml.
Where indicated, PA14 supernatant was heat inactivated (PA14 HI) at 95˚C for 10 min. (C,D)
Cultures were treated with exogenous rhamnolipids or L-rhamnose (10–50 μg/ml) in the
absence of antibiotic. At indicated times, an aliquot was washed and plated to enumerate survi-
vors. All experiments were performed in biological triplicate. Underlying data can be found in
S1 Data. Error bars represent mean ± sd. MHB, Mueller-Hinton broth.
(TIF)
S2 Fig. Pseudomonas-produced toxins inhibit respiration in S. aureus and induce antibiotic
tolerance. (A) S. aureus HG003 was grown to mid-exponential phase in TSB + 100 mM
MOPS in an anaerobic chamber and pre-treated with sterile supernatants from HG003 or
PA14 for 30 min before addition of ciprofloxacin. HG003 was grown aerobically to mid-expo-
nential phase in MHB media and pre-treated with (B) sterile supernatants from P. aeruginosa
strains PA14 wild-type or its isogenic mutants or (C-D) physiologically relevant concentra-
tions of HQNO, PYO, or NaCN for 30 min prior to antibiotic challenge. At indicated times, an
aliquot was washed and plated to enumerate survivors. All experiments were performed in bio-
logical triplicate. Underlying data can be found in S1 Data. Error bars represent mean ± sd.
HQNO, 4-hydroxyquinoline N-oxide; MHB, Mueller-Hinton broth; MOPS, 3-(N-morpho-
lino)propanesulfonic acid; NaCN, sodium cyanide; PYO, pyocyanin; TSB, tryptic soy broth.
(TIF)
S3 Fig. P. aeruginosa supernatant inhibits S. aureus aerobic respiration. (A-C) S. aureus
strain HG003 harboring plasmid PpflB::gfpwas grown to mid-exponential phase and treated
with supernatant from P. aeruginosa clinical isolates or laboratory strains. OD600 and gfp
expression levels were measured every 30 min for 16 h using a Biotek Synergy H1 microplate
reader. All experiments were performed in biological triplicate. Underlying data can be found
in S1 Data. Error bars represent mean ± sd.
(TIF)
S4 Fig. P. aeruginosa endopeptidase LasA induces lysis in S. aureus. S. aureus HG003 was
grown to mid-exponential phase and exposed to sterile supernatants indicated for 30 min
prior to addition of vancomycin 50 μg/ml. (A) At indicated times, an aliquot was removed,
washed, and plated to enumerate survivors. (B) At 24 h post antibiotic treatment, the turbidity
of cultures treated with supernatant from HG003 (red), P. aeruginosa CF isolates (blue), or
burn isolates (green) was measured by absorbance at OD600.
p< 0.05 by one-way ANOVA
and Tukey’s multiple comparisons post test. All experiments were performed in biological
triplicate. Underlying data can be found in S1 Data. Error bars represent mean ± sd. CF, cystic
fibrosis.
(TIF)
S5 Fig. P. aeruginosaLasA lyses heat-killed S. aureus. (A,B) Heat killed S. aureus cells were
incubated with supernatant from P. aeruginosa isolates in a 96-well plate. Lysis of S. aureus was
monitored by measuring OD595 every 5 min for 2 h. All experiments were performed in bio-
logical triplicate. Underlying data can be found in S1 Data. Error bars represent mean ± sd.
(TIF)
S6 Fig. Exposure to P. aeruginosa supernatant alters MRSA antibiotic susceptibility. S.
aureus strain JE-2 was grown to mid-exponential phase and exposed to sterile supernatants
from P. aeruginosa for 30 mins prior to the addition of (A) tobramycin 58 μg/ml or (B) vanco-
mycin 50 μg/ml. At indicated times, an aliquot was removed, washed and plated to enumerate
survivors. All experiments were performed in biological triplicate. Underlying data can be
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found in S1 Data. Error bars represent mean ± sd. MRSA, methicillin-resistant S. aureus.
(TIF)
S7 Fig. P. aeruginosaLasA potentiates vancomycin killing of S. aureus during P. aerugi-
nosa/S. aureus coculture. S. aureus strain HG003 was grown to mid-exponential phase,
exposed to 0.5 ml of stationary phase culture from P. aeruginosa strains PAO1 or PAO1
lasA::tet and 5% BSA for 30 mins prior to addition of vancomycin (50 μg/ml). At indicated
times, an aliquot was removed, washed and plated on selective media to enumerate (A) S.
aureus and (B) P. aeruginosa cells. All experiments were performed in biological triplicate.
Underlying data can be found in S1 Data. Error bars represent mean ± sd.
(TIF)
S8 Fig. Burned mice maintain a high burden of P. aeruginosaPAO1 WT and PAO1
lasA::tet during co-infection. Approximately 1 x 105 CFU S. aureus strain HG003 was admin-
istered subcutaneously alone or in combination with approximately 1 x 103 CFU P. aeruginosa
PAO1 or PAO1 lasA::tn 24 h after burn. Mice were left untreated or administered 110 mg/kg
vancomycin subcutaneously once daily for 2 d. Mice were sacrificed 48 h post infection. (A)
Tissue biopsies at the site of infection were harvested, homogenized and P. aeruginosa burdens
were each enumerated. Data for each group are compiled from 2 independent experiments.
Underlying data can be found in S1 Data. WT, wild-type.
(TIF)
S9 Fig. Correlation analysis of P. aeruginosa exoproduct production and impact on S.
aureus antibiotic susceptibility. (A) HQNO production (measured by mass spectrometry),
and (B) lytic activity (measured by staphylolytic assay) of P. aeruginosa laboratory strains
PAO1 and PA14 and 12 clinical isolates were correlated to the isolate’s impact on S. aureus sus-
ceptibility to (A) ciprofloxacin or (B) vancomycin. The correlation coefficient and p-value for
each analysis is shown. Statistical significance was determined using a two-tailed Pearson’s
chi-squared test. The figures presented summarize data depicted in Figs 1–4.
(TIF)
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